FDA Approves Darolutamide + Docetaxel for mHSPC

On August 5, 2022, the U.S Food and Drug Administration (FDA) approved a supplemental new drug application for darolutamide in combination with docetaxel for the treatment of adult patients with metastatic hormone-sensitive prostate cancer (mHSPC).

For more information read the FDA announcement and the Bayer announcement.

Posted 8/8/2022